Researchers say erectile dysfunction (ED) is common in men with a chronic bacterial infection in gum (called periodontitis). Periodontitis in adults causes tooth loss and increases the risk of cardiovascular disease, stroke, hardening of arteries and inflammation. Researchers analyzed 213,000 participants data, aged between 20 and 80 from five studies done between 2009 and 2014. Earlier studies indicated that
A study in 2003 says erectile dysfunction can be improved by treating periodontitis. As chronic periodontitis was linked to several chronic diseases including erectile dysfunction (ED), patients should focus on cleaning interdental parts to reduce dental plaque formation and gingival inflammation. Senior author of the study is Dr. Zhigang Zhao, Guangzhou Medical University, China and the study findings were published in International Journal of Impotence Research.
Erectile dysfunction : Unable to develop or sustaining hardness or firm erection of the penis when nerves in penis receive signals from the brain during sexual activity or arousal is called erectile dysfunction or impotence. Corpora cavernosa is a part of the penis that contains small blood vessels and works like a sponge. Developing and maintaining erection happens when blood enters and retains within this spongy corpora cavernosa. Erectile dysfunction (ED) problem arises if something blocks brain signals or flow of blood to corpora cavernosa. Symptoms of Erectile dysfunction (ED) are
Causes for erectile dysfunction (ED) are
Treatments for Erectile dysfunction (ED) are
Both Xultophy (made by Novo Nordisk, Denmark) and Soliqua (made by Sanofi, France) are combination drugs approved by FDA for the treatment of type 2 diabetes. They combine long-lasting insulin with GLP-1 to stimulate insulin production in the pancreas and to improve glycemic control. The European Commission has approved Xultophy during 2014 which contains GLP-1 agonist Victoza and Tresiba insulin drug. Similarly, Soliqua contains GLP-1 Lyxumia and Lantus insulin drug. Both these drugs are once in a day injections. Soliqua drug may be launched during January 2017 and Xultophy during the middle of 2017.
A study by researchers from School of Pharmacy, Memorial University of Newfoundlands, Canada says there is no association between higher insulin medication and increased risk of cardiovascular diseases in type 2 diabetes patients. They assured insulin-using patients and healthcare professionals that there are no major risks associated with the use of insulin. Researchers analyzed 6,072 new insulin drug users with type 2 diabetes aged more than 30 years and using metformin from 2001 to 2012 and came to the following conclusion. Author of the study is John-Michael Gamble, PhD.
The Diabetes News Chronicle does not provide medical advice, diagnosis or treatment. Information in Diabetes News Chronicle is to support and not to replace medical advice given by the surgeon or physician or doctor. Published article is not a medical advice by the OWNER of the "Diabetes News Chronicle" website or by the AUTHOR of the article.
Published by Jammi Vasista, Chennai, India.